SMS Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO SMS Pharmaceuticals is Ramesh Potluri, benoemd in Aug1990, heeft een ambtstermijn van 34.25 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 36.88M, bestaande uit 81.4% salaris en 18.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 36.22% van de aandelen van het bedrijf, ter waarde ₹ 7.39B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 2.3 jaar.
Belangrijke informatie
Ramesh Potluri
Algemeen directeur
₹36.9m
Totale compensatie
| Percentage CEO-salaris | 81.4% |
| Dienstverband CEO | 34.3yrs |
| Eigendom CEO | 36.2% |
| Management gemiddelde ambtstermijn | 5.5yrs |
| Gemiddelde ambtstermijn bestuur | 2.3yrs |
Recente managementupdates
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹593m |
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | ₹37m | ₹30m | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
Compensatie versus markt: De totale vergoeding ($USD 436.71K ) Ramesh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 194.43K ).
Compensatie versus inkomsten: De vergoeding van Ramesh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Ramesh Potluri (66 yo)
34.3yrs
Tenure
₹36,875,000
Compensatie
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 34.3yrs | ₹36.88m | 36.22% ₹ 7.4b | |
| Chief Financial Officer | 7.2yrs | ₹2.37m | geen gegevens | |
| Company Secretary & Compliance Officer | 2.8yrs | ₹1.53m | geen gegevens | |
| Executive Director | 3.8yrs | ₹36.83m | 15.74% ₹ 3.2b | |
| Assistant General Manager of HR and Legal | no data | geen gegevens | geen gegevens | |
| Head of HRD and General Manager of Purchases | no data | geen gegevens | geen gegevens |
5.5yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SMSPHARMA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 34.3yrs | ₹36.88m | 36.22% ₹ 7.4b | |
| Executive Director | 4.4yrs | ₹36.83m | 15.74% ₹ 3.2b | |
| Additional Non-Executive Non-Independent Director | less than a year | geen gegevens | 2.58% ₹ 527.6m | |
| Non-Executive & Independent Director | 5.3yrs | ₹245.00k | geen gegevens | |
| Non-Executive & Independent Director | 6.5yrs | ₹590.00k | 0.035% ₹ 7.2m | |
| Additional Non-Executive Independent Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Non-Independent Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Independent Director | less than a year | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SMSPHARMA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.